This past weekend, we went camping in Franconia Notch, New Hampshire.
My six-year-old daughter and four-year-old boy had wanted to go camping for two years, and the trip did not disappoint.
We went with a bunch of other families from our town, Wellesley.
The weather was extremely stormy – cold, wet, and rainy. But it felt like a true adventure.
Due to the rain and wind, my family called it a night at 7pm and retired to our tent to get warm and tell ghost stories.
Eventually, the kids fell asleep, but I couldn’t settle.
The problem was the wind.
Every few minutes, I would hear a gust coming from hundreds of yards away. I would brace myself and wonder, “is this the gust that will send our tent airborne?”
Eventually, at 3am, I figured, “Well the tent has made it this long, it’s probably going to make it through the night.”
And I was able to get some rest.
In the morning, we woke up early as we were on breakfast duty (the plan was to make pancakes).
But to our surprise, all four other tents were gone.
The other families had either gone to a motel for the night or driven back to Wellesley.
At least we were off the hook for breakfast!
As we drove home, we felt a sense of accomplishment for making it through the night. Text after text poured in with some variation of, “I can’t believe you guys survived Campageddon!”
As the news spread, our camping “street cred” skyrocketed in Wellesley.
We got back on Sunday, and I’ve never been so grateful to sleep in my own bed.
It was a good reminder of what’s important. Sure, the market is down and it’s not as much fun to write a newsletter in this environment. But I have two healthy kids, an amazing partner-in-crime/wife, and a roof over my head.
And I get to write about stocks for a living.
Life is good.
And better yet, while the market environment doesn’t feel good, it’s a great time to be buying new stocks.
It was a quiet week last week, but there was one update that I wanted to highlight (full updates below):
Liberated Syndication (LSYN). I had a chance to speak to the CEO of Libsyn. He expects Libsyn to re-file its financials this summer for an August or September small capital raise. This is a positive as the stock will being trading at that time.
The next issue of Cabot Micro-Cap Insider will be published on Wednesday, July 13. As always, if you have any questions, please email me at rich@cabotwealth.com.
Changes This Week
None
Updates
Aptevo (APVO) announced positive data last week from its phase 1b trial in MDS patients treated with APVO436. 36% of patients achieved a remission. As of March 31, 2022, Aptevo has $30MM of net cash and expects to receive an additional $22.5MM over the next few years. Aptevo’s cash burn over the past year was $22MM. As such, it can probably make it another two years without raising cash. However, the company probably does want to raise capital at some point. From a fundamental perspective, Aptevo continues to report good data for its lead compound APVO436 in patients with acute myeloid leukemia (AML). This biotech bear market is no fun, but Aptevo continues to be an asymmetric bet. Original Write-up. Buy under 7.50
Atento S.A. (ATTO) reached a settlement with an activist investor, Kyma Capital, in early June. Kyma owns 8.5% of the company. Under the terms of the agreement, Kyma will get a board seat and will work with the Board of Directors to evaluate all options to increase shareholder value. Kyma also has permission to increase its position to 19.9%. While the most recent quarter was weak, the stock looks very cheap. And the agreement is a possitive. Atento is trading at just 3x EBITDA while peers trade at closer to 12x EBITDA. Original Write-up. Buy under 20.00
Cipher Pharma (CPHRF) reported earnings in May. They were great. Revenue was flat year over year, but EPS increased from $0.05 last year to $0.08 this year. The EPS increase was driven by cost cutting (operating expenses decreased 25%). Meanwhile, ~2% of shares were repurchased during the quarter. Currently has $22MM of net cash on its balance sheet, representing 48% of the company’s market cap. Cash flow should be stable for at least the next 4-5 years which will provide time for the pipeline to emerge. The company continues to move its pipeline forward and evaluate accretive acquisition opportunities. Original Write-up. Buy under 2.00
Cogstate Ltd (COGZF) has had no recent news, but we will get a financial update in July. Cogstate is a profitable, rapidly growing Australian company that is the market leader in computerized cognition testing. The biggest use case is Alzheimer’s Disease, which is a massive and growing market. Cogstate is benefiting from a boom in Alzheimer’s R&D spending which is driving 20%+ revenue growth. Longer term, Cogstate’s direct-to-consumer Alzheimer’s test could accelerate growth even further. Despite a terrific outlook, Cogstate trades at just 24x current earnings. Looking out a few years, this stock could easily double or more. Original Write-up. Buy under 1.80
Crossroads Systems (CRSS) reported earnings last week. The company doesn’t share too much information when it reports earnings, but the key takeaways for me was the following: 1) impact loan generated $1.5MM of net income in the quarter or $6MM on an annualized basis 2) the impact loan portfolio continues to grow the company’s recently announced partnership with Enhanced Capital. The stock is trading at ~12x annualized net income (from impact loans) which seems far too cheap given 1) strong growth potential in the impact loan market and 2) the management team and board of directors have a track record of creating shareholder value (the company paid a special dividend of $40/per share in 2021 due to windfalls from the PPP program). Original Write-up. Buy under 15.00
Currency Exchange International (CURN) reported earnings last week. Results were strong, but not strong enough as the stock has sold off. Revenue increased 109% y/y to $13.3MM. Net operating income increased to $2.9MM up from a loss of $0.6MM last year. Both Banknotes (+103%) and Payments (+127%) grew very strongly. Importantly, management noted that it expects a strong summer travel season which should drive (my opinion) record results. The stock continues to look very cheap. Original Write-up. Buy under 16.00
Dorchester Minerals LP (DMLP) has pulled back a bit with oil prices, but I think it continues to look compelling. Dorchester latest distribution was $0.75, which annualizes to an 11.7% yield. The company is benefiting from high commodity prices. While commodity prices will continue to be volatile, I expect them to remain elevated for the foreseeable future. Dorchester will pay out all windfall profits to shareholders. Original Write-up. Buy under 25.00
Epsilon Energy (EPSN) has pulled back recently, in line with a pullback in natural gas prices. Last year, the company produced tremendous free cash flow and will likely do so again this year. The company currently has $30MM of cash (20% of its market cap) and no debt. Epsilon recently committed to paying a quarterly dividend of $0.0625 per share starting on March 31. This works out to a 3.0% dividend yield. In addition, the company is actively buying back shares (1.1MM share repurchase authorization). Original Write-up. Buy under 8.00
Esquire Financial Holdings (ESQ) had no news this week. It initiated a 9-cent quarterly dividend in April. This works out to a 1% yield. The company reported earnings in late March. Results were excellent, and the investment case remains on track. The company reported Q2 EPS of $0.66, a penny ahead of consensus. Return on equity increased y/y from 13.3% to 15.0%. Esquire remains well capitalized with excellent credit metrics. The company has a long runway for growth, as articulated by CEO Andrew Sagliocca: “There is tremendous potential in both the litigation and payment markets primarily due to the limited number of players and fragmented and inefficient approach to coupling financing, payment processing, and technology. We believe Esquire will be a leader in all three categories in both industries.” Despite its strong outlook, the stock trades at just 12x earnings. Original Write-up. Buy under 35.00
IDT Corporation (IDT) announced quarterly results in early June, and the stock sold off. At a high level, the quarter didn’t look great. Revenue decreased 12% y/y which was driven by a 17% decline in traditional communications revenue. This segment benefitted from the boom in paid calling during the pandemic, but that surge is normalizing. Most importantly, IDT’s high-growth segments continue to grow well. National Retail Solutions (NRS), IDT’s payment terminal business, grew 102% y/y. Net2phone, IDT’s other highly valuable subsidiary, grew recurring revenue by 42%. Further, IDT expects subsidiary growth to contribute to consolidated profitability in the second half of this year. While the spin-off of net2phone has been temporarily delayed, we know that it and NRS will ultimately be monetized. The investment case remains on track and my price target is 55 based on an updated sum-of-the-parts analysis. Original Write-up. Buy under 45.00
Liberated Syndication (LSYN) has had no news recently. However, I had a chance to speak to the CEO this week. He said the team is working through re-filing its financials, and he expects to “go public” again by the end of September. Instead of just “turning on” trading, he would like to raise a little capital and also pick up some coverage from some sell side analysts. He noted the advertising business is growing very well and that the podcast hosting business is growing again. It had experienced limited growth last year given free hosting competition, but business has picked back up. While Libsyn has been a frustrating stock, I think (and hope!) our patience will be rewarded by the of September. Original Write-up. Buy under 5.00
Medexus Pharma (MEDXF) had no news this week. Recently, Medexus announced that the FDA has requested additional data and analysis related to its New Drug Application for Treosulfan. Medac (Medexus’ partner) believes it will be able to provide all the data and analysis by July 2022 (the original 12-month deadline). However, in the case that Medac can’t make the deadline, it can request an extension. In response to the news, the stock has gotten whacked, but I think it is a good buying opportunity. I think the stock is undervalued even if Treosulfan isn’t ultimately approved. I continue to believe that the risk/reward for Medexus looks attractive heading into the second half of the year. Original Write-up. Buy under 3.50
NexPoint Diversified REIT (NXDT) filed an SEC document in early June, which suggests a transition to REIT is imminent. My reading of the document is the SEC should approve NexPoint’s application to deregister unless someone requests a hearing by June 27. As such, the company could get approval as soon as the end of the month. The investment case is on track for NexPoint. It continues to trade at a large discount to NAV, and I expect that gap to close quickly once the REIT transition is complete. Original Write-Up. Buy under 16.00
P10 Holdings (PX) reported another great quarter in May. Revenue increased 32% to $43.3MM while adjusted EBITDA increased 31% to $22.5MM. Assets under management increased 34% to $17.6BN. Higher assets under management will drive continued revenue and earnings growth. The company also announced a $20MM share repurchase. P10 is currently trading at 15x 2022 adjusted EBITDA which is a very reasonable valuation for such a stable business with strong organic growth potential. Original Write-up. Buy under 15.00
RediShred (RDCPF) is my latest recommendation. It’s a Canada-based, leading document destruction services company. Insiders own more than 30% of the company. It has grown revenue at a 31% CAGR and EBITDA at an 80% CAGR over the past 10 years through organic and inorganic growth. Future growth is poised to continue yet the stock trades at just 5x forward EBITDA. I see 100% upside over the next 12 months and significantly more upside looking out a few years. Original Write-up. Buy under 0.70
Truxton (TRUX) reported another great quarter in April with the company reporting its best quarterly earnings ever. The private banking team continues to grow assets in the Nashville area and rising rates are benefiting the portfolio’s net interest margin. Asset quality remains sound with $0 in non-performing loans and $0 in net charge-offs (that’s pretty good!). The Truxton investment case remains on track. The bank will continue to grow loans and earnings prudently while returning excess cash to shareholders through dividends and share buybacks. The stock is trading at just 12.3x annualized earnings. This isn’t the most exciting stock, but it’s a slow and steady winner. Original Write-up. Buy under 75.00
Zedge Inc (ZDGE) reported earnings this week. The stock fell as revenue grew by 18% but declined sequentially. Monthly active users (MAUs) in both developing and developed countries fell sequentially. However, management noted that MAUs are growing again and that they are cautiously optimistic that these trends will continue. Further, the recent quarter included no contribution from the recent acquisition of GuruShots. Given strong recent insider buying, I’m expecting positive news when we hear more details about the integration of GuruShots. The stock remains very cheap trading at 3.4x EBITDA. Original Write-up. Buy under 6.00
| Stock | Price Bought | Date Bought | Price on 6/21/22 | Profit | Rating |
| Aptevo Therapeutics (APVO) | 32.01 | 3/10/21 | 3.70 | -88% | Buy under 7.50 |
| Atento SA (ATTO) | 21.57 | 8/24/21 | 11.66 | -46% | Buy under 20.00 |
| Cipher Pharma (CPHRF) | 1.80 | 10/11/21 | 1.87 | 4% | Buy under 2.00 |
| Cogstate Ltd (COGZF) | 1.70 | 4/13/22 | 1.15 | -32% | Buy under 1.80 |
| Crossroad Systems (CRSS) | 14.10 | 2/9/22 | 12.26 | -13% | Buy under 15.00 |
| Currency Exchange (CURN) | 14.10 | 05/11/22 | 13.15 | -7% | Buy under 16.00 |
| Dorchester Minerals LP (DMLP)* | 10.45 | 10/14/20 | 26.84 | 157% | Buy under 25.00 |
| Epsilon Energy (EPSN) | 5.00 | 8/11/21 | 6.13 | 23% | Buy under 8.00 |
| Esquire Financial Holdings (ESQ) | 34.11 | 10/10/21 | 34.10 | 0% | Buy under 35.00 |
| IDT Corporation (IDT) | 19.37 | 2/10/21 | 25.13 | 30% | Buy under 45.00 |
| Liberated Syndication (LSYN) | 3.06 | 6/10/20 | 3.75 | 23% | Buy under 5.00 |
| Medexus Pharma (MEDXF) | 1.78 | 5/13/20 | 1.64 | -8% | Buy under 3.50 |
| NexPoint Diversified Real Estate Trust (NXDT) | 14.15 | 1/12/22 | 14.92 | 5% | Buy under 16.00 |
| P10 Holdings (PX)** | 2.98 | 4/28/20 | 10.99 | 269% | Buy under 15.00 |
| Truxton Corp (TRUX)* | 72.25 | 12/8/21 | 65.00 | -9% | Buy under 75.00 |
| Zedge (ZDGE) | 5.73 | 3/9/22 | 3.52 | -39% | Buy under 6.00 |
Disclosure: Rich Howe owns shares in LSYN, MEDXF, PIOE, IDT, APVO, DMLP, and NXDT. Rich will only buy shares after he has shared his recommendation with Cabot Micro-Cap Insider members.
Buy means accumulate shares at or around the current price.*Includes dividends received
Hold means just that; hold what you have. Don’t buy, or sell, shares.
Sell means the original reasons for buying the stock no longer apply, and I recommend exiting the position.
Sell a Half means it’s time to take partial profits. Sell half (or whatever portion feels right to you) to lock in a gain and hold on to the rest until another ratings change is issued.